Navigation Links
Personalized antiplatelet treatment improves outcome after PCI
Date:8/28/2012

The findings were presented by Dr Jolanta Siller-Matula from Medical University of Vienna.

Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel.

But measurements of platelet aggregation in clopidogrel treated patients indicate that one patient in four is a non-responder to the drug. Such non-responsiveness is attributed to clopidogrel's extensive hepatic metabolism, polymorphisms of metabolising enzymes and drug-drug interactions, with additional contributions coming from clinical variables such as diabetes, body mass index, acute coronary syndrome, ejection fraction and renal failure. Multiple studies have demonstrated a clear association between non-responsiveness to clopidogrel and adverse clinical events. The strongest relationship was found between poor clopidogrel response and short term events, particularly stent thrombosis.

Personalized antiplatelet treatment involves choosing a therapy based on the results of platelet function testing, a measurement which shows how effective an antiplatelet drug such as clopidogrel is at inhibiting platelet aggregation. Non-responders to the drug can be given a higher dose of clopidogrel or an alternate antiplatelet therapy such as the more potent platelet inhibitors prasugrel or ticagrelor. Personalized antiplatelet treatment only in clopidogrel non-responders would be a therapeutic strategy reaching two goals: increase of clinical efficacy only in patients who are at increased risk for ischemic events without exposing patients with a proper clopidogrel response to bleedings with use of very potent platelet antagonists.

In the MADONNA study (Multiple electrode Aggregometry in patients receiving Dual antiplatelet therapy tO guide treatmeNt with Novel platelet Antagonists), Austrian investigators led by Dr Jolanta Siller-Matula from the Medical University of Vienna and Professor Gnter Christ from Kaiser Franz Josef Hospital in Vienna, investigated whether individualized treatment with platelet inhibitors according to the results of whole blood aggregometry improves clinical outcomes in patients undergoing percutaneous coronary intervention.

A total of 798 patients underwent platelet testing with whole blood aggregometry using the multiple electrode aggregometry (MEA) technique, which allowed patients to be classified as clopidogrel responders or non-responders. Patients were then allocated to the guided group or the non-guided group. In the guided group (n=403) clopidogrel non-responders (26%) received up to four loading doses of clopidogrel or after prasugrel became available, the more potent platelet inhibitor prasugrel. In the non-guided group (n=395) clopidogrel non-responders (25%) were further treated with the standard treatment consisting of clopidogrel and aspirin.

Results showed that patients in the non-guided group were at a 7.9-fold higher risk to develop stent thrombosis compared to the patients in the guided group (1.9% versus 0.2%; p=0.027). Furthermore acute coronary syndrome occurred in 0% of patients in the guided group versus 2.5% in the non-guided group (p=0.001). There were no differences between the two groups in the rates of cardiac death or major bleeding.

"Introducing clopidogrel testing into clinical practice might be feasible: it involves a blood sample and takes ten minutes to get a result," said Dr Siller-Matula, first author of the study. "Providing individualized treatment based on the results of MEA instead of using novel antiplatelet drugs in each patient would save costs of drug therapy of about 410 per patient each year. As individualized antiplatelet therapy seems to be cost-effective, it might be of interest to health authorities."

"Physicians would never adjust doses of antihypertensive drugs without knowing blood pressures; statins, without knowing cholesterol levels; or antidiabetic drugs without knowing the HbA1C levels," she added. "So why are we still treating our patients with platelet inhibitors without being aware of levels of platelet inhibition?"


'/>"/>

Contact: European Society of Cardiology
press@escardio.org
33-049-294-8627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. New method may allow personalized clinical trial for cancer therapies
2. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
3. A new genre of diagnostic tests for the era of personalized medicine
4. Personalized Blood Pressure Therapy May Help Diabetics
5. Little Evidence on Value of Treatments for Autism: Report
6. Reducing the side effects of treatment for prostate cancer
7. Little evidence supports autism treatment options in adolescents
8. pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects
9. Study: Clot removal devices successful tools for acute ischemic stroke treatment
10. Circadian clock research may enable designer plants, and cancer and diabetes treatments
11. NIH launches trial to evaluate anti-inflammatory treatment for preventing heart attacks, strokes, and cardiovascular deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , ... January 21, 2017 , ... Seamild, the largest ... the futuristic vision of its owner and founder. As Oat is recognized globally as ... everybody he knows personally as he believes it is a move to sow the ...
(Date:1/21/2017)... ... 21, 2017 , ... In the United States, 20 million women and 10 ... they often feel shame for having struggled with an eating disorder as well as ... “Rising Strong in Life After an Eating Disorder” -- to be featured at this ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Source Vitál ... and 100 percent pure essential oils, announced the company had a successful visit to ... The annual ECRM event gives companies that work in the nutritional, sports and health ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing ... “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, ... , When asked of her new book, Marjorie says, “‘The Angel’ was written as ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Stock-Callers.com today evaluates the following Drug Manufacturers equities: ... A/S (NYSE: NVO ), Sucampo Pharmaceuticals Inc. (NASDAQ: ... PTX ). These stocks belong to the Healthcare ... finishing near its session lows. As per a NASDAQ report, ... of health care companies in the S&P 500 also were ...
(Date:1/20/2017)... -- Wells Specialty Pharmacy announces the acquisitions and merger of ... Winter Park, Florida and Pharm-EZ Medical, LLC, ... been consolidated into the 3796 Howell Branch Road Facility. ... Chad Tomlinson , former Vice President of Operations, has ... Tomlinson is a Graduate of Florida State University and has ...
(Date:1/19/2017)... 2017 Germany Cataract Surgery ... new report, "Germany Cataract Surgery Devices Market Outlook to ... Surgery Devices market. The report provides value, in millions ... (USD) within market segements - Phacoemulsification Equipment and Ophthalmic ... shares and distribution shares data for each of these ...
Breaking Medicine Technology: